Insights Into Metastatic Castration-Resistant Prostate Cancer

Perspectives on current treatment practices regarding genetic testing in metastatic castration-resistant prostate cancer (mCRPC), first-line treatment of mCRPC, and management of progressive and/or symptomatic mCRPC

Northeast – December 15, 2020
Daniel Petrylak, MD, Yale, Aptitude Health

Faculty Chair

Daniel Petrylak, MD

Yale University, CT, US

Example Report

Start discovering the insights

View Report


  • A virtual, moderated roundtable discussion focusing on the treatment of mCRPC was held on December 15, 2020
  • Disease state and data presentations were developed in conjunction with Daniel Petrylak, MD, a medical expert from Yale School of Medicine
  • Insights into genetic testing methods and therapies were obtained, with a particular focus on olaparib, rucaparib, genetic testing (somatic/germline); BRCA, HRR, and PALB2 mutations


  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • Attendees of the roundtable represented community oncologists from New Jersey, Pennsylvania, Vermont, Massachusetts, and New York

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.